Abstract Library

#2072 Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic Grade 3 Neuroendocrine Neoplasms: A Retrospective International Multicenter Study

Introduction: Gastroenteropancreatic (GEP) grade 3 neuroendocrine neoplasms (NEN G3) are rare, highly malignant neoplasms with poor prognosis and limited therapeutic options. Median survival following chemotherapy is only 10-12 months.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Skovgaard D

Authors: Skovgaard D, Fazio N, Granberg D, Grozinsky-Glasberg S, Ahmadzadehfar H,

Keywords: neuroendocrine neoplasms, WHO grade 3, PRRT, Progression-free survival, Overall survival,

#1054 Radioembolization with 90Y-Labelled Resin Microspheres in Patients with Liver Metastases from Neuroendocrine Tumors

Introduction: Hepatic arterial embolization with 90Y-labelled microspheres is a method of delivering radioactivity to liver tumors, that has been used to treat primary hepatocellular carcinomas and liver metastases from colorectal carcinomas and neuroendocrine tumors.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Granberg D

Authors: Ebeling-Barbier C, Garske-Roman U, Antonodimitrakis P, Sandström M, Nyman R,

Keywords: radioembolization, neuroendocrine, liver metastases,

#861 Targeted Next Generation Sequencing in the Screening for Familial Neuroendocrine Tumor Syndromes: A Tool for Personalized Medicine

Introduction: Multiple syndromes are described as conferring susceptibility to NETs; MEN1 & 2, NF1, familial PGL 1-5, TSC, VHL and germline mutations in the HIF2A, MAX, or TMEM127. Genetic testing covering these diagnoses may be extensively resource-demanding using traditional techniques due to the large extent of these loci.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Crona J, Stålberg P, Granberg D, Welin S, Hellman P,

Keywords: neuroendocrine tumor, genetics ,

#658 Somatic Mutations in H-RAS in Sporadic Pheochromocytoma and Paraganglioma Identified by Exome Sequencing.

Introduction: Up to 60% of pheochromocytoma (PCC) and paraganglioma (PGL) are associated with mutations in established PCC and PGL susceptibility loci. A majority of unexplained cases are characterized by an increased activity of the RAS/RAF/ERK signalling pathway. Mutations in RAS subtypes H, K and N are common in human cancers, however, previous studies have been inconsistent regarding the mutational status of RAS in PCC and PGL.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Crona J, Delgado Verdugo A, Stålberg P, Granberg D, Hellman P,

Keywords: H-RAS, pheochromocytoma,

#503 Long-Term Stable Disease with Everolimus in a Patient with Advanced Pancreatic Neuroendocrine Tumor Enrolled in RADIANT-1

Introduction: The phase II open-label RADIANT-1 study evaluated the safety and efficacy of Everolimus (E, 10 mg/d) ± octreotide LAR (O) in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET) after chemotherapy failure. Objective tumor response was 9.6% in the E group and 4.4% in the E+O group (all partial), and stable disease (SD) was 68% and 80%.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Falkerby J, Granberg D, Eriksson B, Skogseid B, Öberg K,

Keywords: neuroendocrine, Everolimus, pancreatic,